The Correlation of CD4+ T-Lymphocyte Count and Chemokine Ligand 13 Levels in Human Immunodeficiency Virus Patients Receiving Anti-retrovirus Therapy in Sanglah Central General Hospital

Komang Juwita Endrawati; Ni Kadek Mulyantari; Sianny Herawati; Anak Agung Wiradewi Lestari; I Nyoman Wande; Ida ayu Putri Wirawati

doi:10.3889/oamjms.2022.8961

Authors

Komang Juwita Endrawati Department of Clinical Pathology, Trainee Clinical Pathology, Medical Faculty, Udayana University, Bali, Indonesia
Ni Kadek Mulyantari Departement of Clinical Pathology, Medical Faculty, Sanglah Hospital, Bali, Indonesia
Sianny Herawati Departement of Clinical Pathology, Medical Faculty, Sanglah Hospital, Bali, Indonesia
Anak Agung Wiradewi Lestari Departement of Clinical Pathology, Medical Faculty, Sanglah Hospital, Bali, Indonesia
I Nyoman Wande Departement of Clinical Pathology, Medical Faculty, Sanglah Hospital, Bali, Indonesia
Ida ayu Putri Wirawati Departement of Clinical Pathology, Medical Faculty, Sanglah Hospital, Bali, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2022.8961

Keywords:

Human immunodeficiency virus, Cluster of differentiation 4 , Chemokine ligand 13

Abstract

BACKGROUND: Human immunodeficiency virus (HIV) infection is an infectious disease caused by the HIV-1 or HIV-2 virus. Cluster of differentiation 4+ (CD4+) T lymphocytes have an important role in the immune process. Chemokine Ligand 13 (CXCL13) is chemotactic for receptor-expressing cells (CXCR5), including B cells and follicular helper (Tfh) T cells. CXCL13 examination can be used to detect HIV antibodies and as a marker of disease progression and monitoring anti-retrovirus therapy (ART) in HIV-infected patients. Giving ART will reduce CXCL13 levels and show B cell activation, so CXCL13 can be used as a new marker of immune or antibody formation during acute or chronic HIV infection. CXCL13 examination can be used to detect HIV antibodies and as a marker of disease progression and monitoring ART in HIV-infected patients. Giving ART will reduce CXCL13 levels and show B cell activation, so CXCL13 can be used as a new marker of immune or antibody formation during acute or chronic HIV infection.

AIM: The aim of the study was to propose a study on the relationship between CD4+ T lymphocyte levels and CXCL13 levels in HIV patients who had received ART at the Sanglah Central General Hospital (RSUP), Denpasar. This study was start from March 2021 to August 2021 at the Sanglah Central General Hospital.

MATERIALS AND METHODS: This study used analytic observational study with a cross-sectional design, conducted at the Voluntary Counseling and Testing and the Clinical Pathology Laboratory at Sanglah Central General Hospital with 55 samples include in inclusion criteria.

RESULTS: In this study, the mean age of the research subjects was 42.18 ± 10.31 years with 58.2% male, 41.8% female having received ART with a mean of 63 months. The average number of CD4+ T lymphocytes was 451.53 ± 295.118. Median CXCL13 level was 50,551. The correlation between CXCL13 levels and the number of CD4+ T lymphocytes was −0.209. This correlation was not significant with p = 0.127 (p < 0.05), then partial correlation was performed. The partial correlation of CXCL13 levels and the number of CD4+ T lymphocytes was −0.308, a negative direction indicating there was an inverse correlation. This correlation is a significant with p = 0.023 (p < 0.05) after partial correlation and is in the category of weak correlation.

CONCLUSIONS: There are a significant negative correlation after partial correlation of CXCL13 levels and the number of CD4+ T lymphocytes in HIV patients at Sanglah Hospital during the treatment phase.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

World Health Organization. New Progress and Guidance on HIV Treatment. Geneva: World Health Organization; 2010. p. 1300.

Kobayashi S, Murata K, Shibuya H, Morita M, Ishikawa M, Furu M, et al. A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum. 2013;65(12):3063-72. https://doi.org/10.1002/art.38173 PMid:24022618 DOI: https://doi.org/10.1002/art.38173

Rao DA. T cells that help B cells in chronically inflamed tissues. Front Immunol. 2018;9:1924. https://doi.org/10.3389/fimmu.2018.01924 PMid:30190721 DOI: https://doi.org/10.3389/fimmu.2018.01924

Roider J, Zachary Porterfield J, Ogongo P, Muenchhoff M, Adland E, Groll A, et al. plasma IL-5 but not CXCL13 correlates with neutralization breadth in HIV-infected children. Front Immunol. 2019;10:1497. https://doi.org/10.3389/fimmu.2019.01497 PMid:31333650 DOI: https://doi.org/10.3389/fimmu.2019.01497

Mehraj V, Ramendra R, Isnard S, Dupuy FP, Lebouché B, Costiniuk C, et al. CXCL13 as a biomarker of immune activation during early and chronic HIV infection. Front Immunol. 2019;10:289. https://doi.org/10.3389/fimmu.2019.00289 PMid:30846990 DOI: https://doi.org/10.3389/fimmu.2019.00289

Moysi E, Petrovas C, Koup RA. The role of follicular helper CD4 T cells in the development of HIV-1 specific broadly neutralizing antibody responses. Retrovirology. 2018;15:54. DOI: https://doi.org/10.1186/s12977-018-0437-y

Bekele YF, Chiodi F, Sui Y, Berzofsky JA. The role of CXCL13 in antibody responses to hiv-1 infection and vaccination. Front Immunol. 2021;12:638872. https://doi.org/10.3389/fimmu.2021.638872 PMid:33732259 DOI: https://doi.org/10.3389/fimmu.2021.638872

Boswell KL, Paris R, Boritz E, Ambrozak D, Yamamoto T, Darko S, et al. Loss of circulating CD4 T cells with B cell helper function during chronic HIV Infection. PLoS Pathog. 2014;10(1):e1003853. https://doi.org/10.1371/journal.ppat.1003853 PMid:24497824 DOI: https://doi.org/10.1371/journal.ppat.1003853

Cohen KW, Dugast AS, Alter G, McElrath MJ, Stamatatos L. HIV-1 single-stranded RNA induces CXCL13 secretion in human monocytes via TLR7 activation and plasmacytoid dendritic cell-derived Type I IFN. J Immunol. 2015;194(6):2769-75. https://doi.org/10.4049/jimmunol.1400952 PMid:25667414 DOI: https://doi.org/10.4049/jimmunol.1400952

Cagigi A, Mowafi F, Dang LV, Tenner-Racz K, Atlas A, Grutzmeier S, et al. Altered expression of the receptor-ligand pair CXCR5/CXCL13 in B cells during chronic HIV-1 infection. Blood. 2008;112(12)4401. https://doi.org/10.1182/blood-2008-02-140426 PMid:18780835 DOI: https://doi.org/10.1182/blood-2008-02-140426

Blc H, Elisa BC. Human BLC (B-Lymphocyte Chemoattractant) ELISA Kit. Vol. 7368. Wuhan, China: Elabscience; 2020.

Jose S. BD Multitest TM R x Only. United States: Becton, Dickinson and Company;2017.

Ladyani F, Kiristianingsih A. Hubungan Antara Jumlah CD4 Pada Pasien Yang terinfeksi HIV/AIDS Dengan Infeksi Oportunistik di Rumah Sakit Umum Abdul Moeloek Bandar Lampung Tahun 2016. J K Unila. 2019;3(1):34-41. https://doi.org/10.23960/jk%20unila.v3i1.2201

Ratha IP, Indrawan IG. The characteristics of opportunistic infections among AIDS patiaents in BRSU tabanan in 2019. Warmadewa Med J. 2019;4(2):50-6. http://doi.org/10.22225/wmj.4.2.1201.50-56

Celikbas A, Ergonul O, Baykam N, Eren S, Esener H, Erolu M, et al. Epidemiologic and clinical characteristics of HIV/AIDS patients in Turkey, where the prevalence is the lowest in the region. J Int Assoc Physicians AIDS Care. 2008;7(1):42-5. DOI: https://doi.org/10.1177/1545109707306575

NSW Ministry of Health. NSW HIV Strategy 20162020: Quarter 4 and Annual 2017 Data Report. New South Wales: Ministry of Health 2019; Available from: http://www.health.nsw.gov.au/endinghiv/Pages/tools-and-data.aspx [Last accessed on 2021 Aug 20].

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41(3):361-72. https://doi.org/10.1086/431484 PMid:16007534 DOI: https://doi.org/10.1086/431484

Serawit D, Alemayehu T, Fiker T. Pattern and predictors of cluster of differentiation 4 (CD4) cell count recovery among cohorts of human immunodeficiency virus (HIV)-infected patients on antiretroviral therapy in Hawassa University Referral Hospital. J AIDS HIV Res. 2018;10(3):40-8. DOI: https://doi.org/10.5897/JAHR2017.0425

Ebonyi AO. Factors associated with a low CD4 count among HIV-1 infected patients at enrolment into HAART in Jos, Nigeria. Br J Med Med Res. 2014;4(13):2536-45. DOI: https://doi.org/10.9734/BJMMR/2014/8469

Nurmawati T, Sari YK, Hidayat AP. Hubungan antara lama pengobatan dengan jumlah CD4 pada penderita HIV/AIDS yang menjalankan program pengobatan antiretrovial (ARV). J Ners dan Kebidanan. 2019;6(2):197-202. https://doi.org/10.26699/jnk.v6i2.ART.p197-202 DOI: https://doi.org/10.26699/jnk.v6i2.ART.p197-202

Yogani I, Karyadi TH, Uyainah A, Koesnoe S. Faktor-faktor yang berhubungan dengan kenaikan CD4 pada pasien HIV yang mendapat highly active antiretroviral therapy dalam 6 bulan pertama. J Penyakit Dalam Indonesia. 2017;2(4):217. https://doi.org/10.7454/jpdi.v2i4.89 DOI: https://doi.org/10.7454/jpdi.v2i4.89

Utama MS, Merati TP. Association of opportunistic infections with HIV-RNA and CD4 cell count in pre ARV and ARV failure at the care support treatment clinic of sanglah hospital, Bali. J Epidemiol Res. 2015;2(2):13-7. DOI: https://doi.org/10.5430/jer.v2n2p13

Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, et al. CXCL13 is a plasma biomarker of germinal center activity. Proc Natl Acad Sci U S A. 2016;113(10):2702-7 PMid:26908875 DOI: https://doi.org/10.1073/pnas.1520112113

Anderson JL, Khoury G, Fromentin R, Solomon A, Chomont N, Sinclair E, et al. Human immunodeficiency virus (HIV)- infected CCR6+ rectal CD4+ T cells and HIV persistence on antiretroviral therapy. J Infect Dis. 2020;221(5):744-55. https://doi.org/10.1093/infdis/jiz509 PMid:31796951 DOI: https://doi.org/10.1093/infdis/jiz509